Immunomodulatory effect of melatonin in SK-LU-1 human lung adenocarcinoma cells co-cultured with peripheral blood mononuclear cells

Cell Proliferation

Volumn 47, Issue 5, 2014, Pages 406-415

  Plaimee, P ^a   Khamphio, M ^a   Weerapreeyakul, N ^a   Barusrux, S ^a   Johns, N P ^a  

^a KHON KAEN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANNEXIN; FLUORESCENT DYE; GLUTATHIONE; HYDROGEN PEROXIDE; MELATONIN; PROPIDIUM IODIDE; SUPEROXIDE; ANTINEOPLASTIC AGENT; ANTIOXIDANT;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL LINE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL POPULATION; CELL VIABILITY; COCULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INCUBATION TIME; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; OXIDATIVE STRESS; PERIPHERAL BLOOD MONONUCLEAR CELL; SK LU 1 CELL LINE; ADENOCARCINOMA; BIOSYNTHESIS; CELL PROLIFERATION; DRUG EFFECTS; G1 PHASE CELL CYCLE CHECKPOINT; IMMUNOLOGY; LUNG NEOPLASMS; MONONUCLEAR CELL; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; ANTIOXIDANTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; COCULTURE TECHNIQUES; G1 PHASE CELL CYCLE CHECKPOINTS; GLUTATHIONE; HUMANS; IMMUNOMODULATION; LEUKOCYTES, MONONUCLEAR; LUNG NEOPLASMS; MELATONIN; OXIDATIVE STRESS;

EID: 84908658246     PISSN: 09607722     EISSN: 13652184     Source Type: Journal    
DOI: 10.1111/cpr.12119     Document Type: Article

References (56)

1. Ashworth A, Rodrigues G, Boldt G, Palma D (2013) Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer 20, 376-379.
2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J. Clin. 61, 69-90.
3. Stahel R, Peters S, Baas P, Brambilla E, Cappuzzo F, De Ruysscher D et al. (2013) Strategies for improving outcomes in NSCLC: a look to the future. Lung Cancer 8, 390-395.
4. Stehle JH, Saade A, Rawashdeh O, Ackermann K, Jilg A, Sebesteny T et al. (2011) A survey of molecular details in the human pineal gland in the light of phylogeny, structure, function and chronobiological diseases. J. Pineal Res. 51, 17-43.
5. Reiter RJ, Rosales-Corral S, Coto-Montes A, Boga JA, Tan DX, Davis JM et al. (2011) The photoperiod, circadian regulation and chronodisruption: the requisite interplay between the suprachiasmatic nuclei and the pineal and gut melatonin. J. Physiol. Pharmacol. 62, 269-274.
6. Hardeland R, Madrid JA, Tan DX, Reiter RJ (2012) Melatonin, the circadian multioscillator system and health: the need for detailed analyses of peripheral melatonin signaling. J. Pineal Res. 52, 139-166.
7. Peres MF (2011) Melatonin for migraine prevention. Curr. Pain Headache Rep. 15, 334-335.
8. Miano S, Parisi P, Pelliccia A, Luchetti A, Paolino MC, Villa MP (2008) Melatonin to prevent migraine or tension-type headache in children. Neurol. Sci. 29, 285-287.
9. Korkmaz A, Reiter RJ, Topal T, Manchester LC, Oter S, Tan DX (2009) Melatonin: an established antioxidant worthy of use in clinical trials. Mol. Med. 15, 43-50.
10. El-Sokkary GH (2008) Melatonin and vitamin C administration ameliorate diazepam-induced oxidative stress and cell proliferation in the liver of rats. Cell Prolif. 41, 168-176.
11. Mauriz JL, Collado PS, Veneroso C, Reiter RJ, Gonzalez-Gallego J (2012) A review of the molecular aspects of melatonin's anti-inflammatory actions: recent insights and new perspectives. J. Pineal Res. 54, 1-14.
12. Cutando A, Lopez-Valverde A, Arias-Santiago S, De Vicente J, De Diego RG (2012) Role of melatonin in cancer treatment. Anticancer Res. 32, 2747-2753.
13. Liu F, Ng TB, Fung MC (2001) Pineal indoles stimulate the gene expression of immunomodulating cytokines. J. Neural. Transm. 108, 397-405.
14. Ram PT, Dai J, Yuan L, Dong C, Kiefer TL, Lai L et al. (2002) Involvement of the mt1 melatonin receptor in human breast cancer. Cancer Lett. 179, 141-150.
15. Wang J, Xiao X, Zhang Y, Shi D, Chen W, Fu L et al. (2012) Simultaneous modulation of COX-2, p300, Akt, and Apaf-1 signaling by melatonin to inhibit proliferation and induce apoptosis in breast cancer cells. J. Pineal Res. 53, 77-90.
16. Martin-Renedo J, Mauriz JL, Jorquera F, Ruiz-Andres O, Gonzalez P, Gonzalez-Gallego J (2008) Melatonin induces cell cycle arrest and apoptosis in hepatocarcinoma HepG2 cell line. J. Pineal Res. 45, 532-540.
17. Ordonez R, Carbajo-Pescador S, Prieto-Dominguez N, Garcia-Palomo A, Gonzalez-Gallego J, Mauriz JL (2014) Inhibition of matrix metalloproteinase-9 and nuclear factor kappa B contribute to melatonin prevention of motility and invasiveness in HepG2 liver cancer cells. J. Pineal Res. 56, 20-30.
18. Buyukavci M, Ozdemir O, Buck S, Stout M, Ravindranath Y, Savasan S (2006) Melatonin cytotoxicity in human leukemia cells: relation with its pro-oxidant effect. Fundam. Clin. Pharmacol. 20, 73-79.
19. Lowe SW, Lin AW (2000) Apoptosis in cancer. Carcinogenesis 21, 485-495.
20. el-Domeiri AA, Das Gupta TK (1973) Reversal by melatonin of the effect of pinealectomy on tumor growth. Cancer Res. 33, 2830-2833.
21. Biemar F, Foti M (2013) Global progress against cancer-challenges and opportunities. Cancer Biol. Med. 10, 183-186.
22. Swann JB, Smyth MJ (2007) Immune surveillance of tumors. J. Clin. Invest. 117, 1137-1146.
23. Smyth MJ, Cretney E, Kershaw MH, Hayakawa Y (2004) Cytokines in cancer immunity and immunotherapy. Immunol. Rev. 202, 275-293.
24. Mellman I, Coukos G, Dranoff G (2011) Cancer immunotherapy comes of age. Nature 480, 480-489.
25. Kuhlwein E, Irwin M (2001) Melatonin modulation of lymphocyte proliferation and Th1/Th2 cytokine expression. J. Neuroimmunol. 117, 51-57.
26. Arias J, Melean E, Valero N, Pons H, Chacin-Bonilla L, Larreal Y et al. (2003) Effect of melatonin on lymphocyte proliferation and production of interleukin-2 (IL-2) and interleukin-1 beta (IL-1 beta) in mice splenocytes. Invest. Clin. 44, 41-50.
27. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Goberna R, Guerrero JM (1998) Involvement of nuclear binding sites for melatonin in the regulation of IL-2 and IL-6 production by human blood mononuclear cells. J. Neuroimmunol. 92, 76-84.
28. Garcia-Maurino S, Gonzalez-Haba MG, Calvo JR, Rafii-El-Idrissi M, Sanchez-Margalet V, Goberna R et al. (1997) Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. J. Immunol. 159, 574-581.
29. Garcia-Maurino S, Pozo D, Carrillo-Vico A, Calvo JR, Guerrero JM (1999) Melatonin activates Th1 lymphocytes by increasing IL-12 production. Life Sci. 65, 2143-2150.
30. Huang Y-M LH, Wei J-E, Lin J, Zhou R-X (2008) Effect of pinealectomy and melatonin on IL-7 expression of rat thymic epithelial cells. Acta Anat. Sin. 39, 901-905.
31. Mocchegiani E, Perissin L, Santarelli L, Tibaldi A, Zorzet S, Rapozzi V et al. (1999) Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL-2. Int. J. Immunopharmacol. 21, 27-46.
32. Maestroni GJ, Covacci V, Conti A (1994) Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice. Cancer Res. 54, 2429-2432.
33. Lissoni P, Rovelli F, Brivio F, Brivio O, Fumagalli L (1998) Circadian secretions of IL-2, IL-12, IL-6 and IL-10 in relation to the light/dark rhythm of the pineal hormone melatonin in healthy humans. Nat. Immun. 16, 1-5.
34. Morrey KM, McLachlan JA, Serkin CD, Bakouche O (1994) Activation of human monocytes by the pineal hormone melatonin. J. Immunol. 153, 2671-2680.
35. Sanchez-Sanchez AM, Martin V, Garcia-Santos G, Rodriguez-Blanco J, Casado-Zapico S, Suarez-Garnacho S et al. (2011) Intracellular redox state as determinant for melatonin antiproliferative vs cytotoxic effects in cancer cells. Free Radic. Res. 45, 1333-1341.
36. Fic M, Podhorska-Okolow M, Dziegiel P, Gebarowska E, Wysocka T, Drag-Zalesinska M et al. (2007) Effect of melatonin on cytotoxicity of doxorubicin toward selected cell lines (human keratinocytes, lung cancer cell line A-549, laryngeal cancer cell line Hep-2). In Vivo 21, 513-518.
37. Feighery C, Whelan CA, Weir DG, Greally JF (1978) In vitro studies of suppressor cell function in human peripheral blood mononuclear cells. Clin. Exp. Immunol. 32, 459-465.
38. Gomes NE, Brunialti MK, Mendes ME, Freudenberg M, Galanos C, Salomao R (2010) Lipopolysaccharide-induced expression of cell surface receptors and cell activation of neutrophils and monocytes in whole human blood. Braz. J. Med. Biol. Res. 43, 853-858.
39. Yeap SK, Alitheen NB, Ali AM, Omar AR, Raha AR, Suraini AA et al. (2007) Effect of Rhaphidophora korthalsii methanol extract on human peripheral blood mononuclear cell (PBMC) proliferation and cytolytic activity toward HepG2. J. Ethnopharmacol. 114, 406-411.
40. Wang Y, Zhu Y, Zhang L, Tian W, Hua S, Zhao J et al. (2012) Insulin promotes proliferation, survival, and invasion in endometrial carcinoma by activating the MEK/ERK pathway. Cancer Lett. 322, 223-231.
41. Park WH, Han YW, Kim SH, Kim SZ (2007) An ROS generator, antimycin A, inhibits the growth of HeLa cells via apoptosis. J. Cell. Biochem. 102, 98-109.
42. Wan XS, Zhou Z, Kennedy AR (2003) Adaptation of the dichlorofluorescein assay for detection of radiation-induced oxidative stress in cultured cells. Radiat. Res. 160, 622-630.
43. Bishayee K, Ghosh S, Mukherjee A, Sadhukhan R, Mondal J, Khuda-Bukhsh AR (2013) Quercetin induces cytochrome-c release and ROS accumulation to promote apoptosis and arrest the cell cycle in G2/M, in cervical carcinoma: signal cascade and drug-DNA interaction. Cell Prolif. 46, 153-163.
44. Sliwkowski MX, Mellman I (2013) Antibody therapeutics in cancer. Science 341, 1192-1198.
45. Drazen DL, Nelson RJ (2001) Melatonin receptor subtype MT2 (Mel 1b) and not mt1 (Mel 1a) is associated with melatonin-induced enhancement of cell-mediated and humoral immunity. Neuroendocrinology 74, 178-184.
46. Gonzalez-Haba MG, Garcia-Maurino S, Calvo JR, Goberna R, Guerrero JM (1995) High-affinity binding of melatonin by human circulating T lymphocytes (CD4+). FASEB J. 9, 1331-1335.
47. Carrillo-Vico A, Lardone PJ, Fernandez-Santos JM, Martin-Lacave I, Calvo JR, Karasek M et al. (2005) Human lymphocyte-synthesized melatonin is involved in the regulation of the interleukin-2/interleukin-2 receptor system. J. Clin. Endocrinol. Metab. 90, 992-1000.
48. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ (2005) A review of the multiple actions of melatonin on the immune system. Endocrine 27, 189-200.
49. Finkel T (2011) Signal transduction by reactive oxygen species. J. Cell Biol. 194, 7-15.
50. Panieri E, Gogvadze V, Norberg E, Venkatesh R, Orrenius S, Zhivotovsky B (2013) Reactive oxygen species generated in different compartments induce cell death, survival, or senescence. Free Radic. Biol. Med. 57, 176-187.
51. Lo YL, Wang W (2013) Formononetin potentiates epirubicin-induced apoptosis via ROS production in HeLa cells in vitro. Chem. Biol. Interact. 205, 188-197.
52. Deponte M (2013) Glutathione catalysis and the reaction mechanisms of glutathione-dependent enzymes. Biochim. Biophys. Acta 5, 2.
53. Menon SG, Sarsour EH, Spitz DR, Higashikubo R, Sturm M, Zhang H et al. (2003) Redox regulation of the G1 to S phase transition in the mouse embryo fibroblast cell cycle. Cancer Res. 63, 2109-2117.
54. Gotoh Y, Noda T, Iwakiri R, Fujimoto K, Rhoads CA, Aw TY (2002) Lipid peroxide-induced redox imbalance differentially mediates CaCo-2 cell proliferation and growth arrest. Cell Prolif. 35, 221-235.
55. Huang S, Ingber DE (2002) A discrete cell cycle checkpoint in late G(1) that is cytoskeleton-dependent and MAP kinase (Erk)-independent. Exp. Cell Res. 275, 255-264.
56. Benitez-King G (2006) Melatonin as a cytoskeletal modulator: implications for cell physiology and disease. J. Pineal Res. 40, 1-9.